×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PMVP – pmv pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PMVP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/18
01:19 pm
pmvp
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/12
08:00 am
pmvp
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
Medium
Report
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
11/7
01:15 am
pmvp
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
10/24
11:39 am
pmvp
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Low
Report
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
10/13
04:21 pm
pmvp
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
Medium
Report
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]
10/13
04:01 pm
pmvp
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Medium
Report
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9/10
07:24 am
pmvp
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation [Yahoo! Finance]
High
Report
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation [Yahoo! Finance]
9/10
07:00 am
pmvp
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
High
Report
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
08:01 am
pmvp
Form 10-Q PMV Pharmaceuticals, For: Sep 30
Medium
Report
Form 10-Q PMV Pharmaceuticals, For: Sep 30
11/12
08:00 am
pmvp
Form 8-K PMV Pharmaceuticals, For: Nov 12
Medium
Report
Form 8-K PMV Pharmaceuticals, For: Nov 12
11/12
08:00 am
pmvp
Form SCHEDULE 13G/A PMV Pharmaceuticals, Filed by: Sio Capital Management, LLC
Medium
Report
Form SCHEDULE 13G/A PMV Pharmaceuticals, Filed by: Sio Capital Management, LLC
10/29
04:12 pm
pmvp
Form 4 PMV Pharmaceuticals, For: Oct 27 Filed by: Mack David Henry
Low
Report
Form 4 PMV Pharmaceuticals, For: Oct 27 Filed by: Mack David Henry
10/27
05:19 pm
pmvp
Form 4 PMV Pharmaceuticals, For: Oct 23 Filed by: ORBIMED ADVISORS LLC
Medium
Report
Form 4 PMV Pharmaceuticals, For: Oct 23 Filed by: ORBIMED ADVISORS LLC
10/27
05:12 pm
pmvp
Form SCHEDULE 13D/A PMV Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Medium
Report
Form SCHEDULE 13D/A PMV Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
10/23
06:39 pm
pmvp
Form 144 PMV Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Low
Report
Form 144 PMV Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
9/23
08:35 pm
pmvp
Form SCHEDULE 13G PMV Pharmaceuticals, Filed by: TANG CAPITAL MANAGEMENT LLC
Medium
Report
Form SCHEDULE 13G PMV Pharmaceuticals, Filed by: TANG CAPITAL MANAGEMENT LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: